Loading...

GUJTHEM Gujarat Themis Biosyn Ltd Company Mergers Announcement

Gjrt

GJTH

Gujarat Themis Biosyn Ltd

(GUJTHEM)

2024 Announcement

Show Summary

Summary

Compliance Certificate

Management Change

Merger Withdrawal

Compliance Report Filed

Financial Results Released

Investor Presentation

Management Change

Production Commencement

Certificate Submission

Equity Shares Listing

Financial Results Published

CFO Appointment

Investor Presentation

Compliance Certificate

RTA Name Change

Amalgamation Announcement

Amalgamation Announcement

Financial Results

Investor Presentation

Management Change

Management Changes

Director Resignation

Compliance Certificate

Postal Ballot Notice

New Appointments

Bonus Shares Allotment

Resignation Announcement

Publication of Financial Re...

Investor Presentation

Change in Directorate

Cessation Announcement

Certificate Submission

Newspaper Advertisement

Compliance Report Submission

Investor Presentation

Financial Results Publication

Change in Management

Compliance Certificate Subm...

Compliance Certificate

Certificate Submission

Advertisement Publication

Investor Presentation

Certificate Submission

Cessation of Subsidiary Status

Q2 & H1 FY 23-24 Earnings Call

Newspaper Publication

Investor Presentation

Conference Call Invite

Certificate Submission

Changes in Revenue Recognit...

Financial Statements

Reaffirmed ratings

Management Changes

Equity, Debt, VC, Private E...

Appointments/Resignations

Earnings Transcript Release

Earnings Call Recording

Results Release

Rights Offerings

Financial Results

Related Party Transactions

External Links:

Data:

Gujarat Themis Biosyn Limited and Themis Medicare Limited have approved an amalgamation plan, subject to various regulatory approvals, with a share exchange ratio of 118 shares of TML for every 100 shares of GTBL held by shareholders.

AI Assistant

Gujarat Themis Biosyn Ltd

2024

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.